{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T22:13:50Z","timestamp":1790115230574,"version":"4.0.1"},"reference-count":23,"publisher":"Elsevier BV","issue":"18","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American College of Cardiology"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.jacc.2022.08.772","type":"journal-article","created":{"date-parts":[[2022,10,24]],"date-time":"2022-10-24T17:40:12Z","timestamp":1666633212000},"page":"1721-1731","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Cardiovascular Effects of Canagliflozin in\u00a0Relation to Renal Function and\u00a0Albuminuria"],"prefix":"10.1016","volume":"80","author":[{"given":"Ashish","family":"Sarraju","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Bakris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher P.","family":"Cannon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Cherney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.V.","family":"Damaraju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5080-6083","authenticated-orcid":false,"given":"Gemma A.","family":"Figtree","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jagadish","family":"Gogate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Greene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiddo J.L.","family":"Heerspink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"James L.","family":"Januzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0490-7465","authenticated-orcid":false,"given":"Bruce","family":"Neal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meg J.","family":"Jardine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaime","family":"Blais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikhail","family":"Kosiborod","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adeera","family":"Levin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ildiko","family":"Lingvay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew R.","family":"Weir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vlado","family":"Perkovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth W.","family":"Mahaffey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacc.2022.08.772_bib1","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1016\/S0140-6736(10)60484-9","article-title":"Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies","volume":"375","author":"Sarwar","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2022.08.772_bib2","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1002\/dmrr.2793","article-title":"The relationship between three eGFR formulas and hospitalization for heart failure in 54 486 individuals with type 2 diabetes","volume":"32","author":"Tancredi","year":"2016","journal-title":"Diabetes Metab Res Rev"},{"key":"10.1016\/j.jacc.2022.08.772_bib3","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.kint.2017.07.013","article-title":"Glomerular hyperfiltration is a predictor of adverse cardiovascular outcomes","volume":"93","author":"Reboldi","year":"2018","journal-title":"Kidney Int"},{"key":"10.1016\/j.jacc.2022.08.772_bib4","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.2337\/dc14-1296","article-title":"Diabetic kidney disease: a report from an ADA Consensus Conference","volume":"37","author":"Tuttle","year":"2014","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jacc.2022.08.772_bib5","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1681\/ASN.2008121270","article-title":"Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes","volume":"20","author":"Ninomiya","year":"2009","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.jacc.2022.08.772_bib6","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2022.08.772_bib7","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2022.08.772_bib8","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/s41569-020-0406-8","article-title":"SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control","volume":"17","author":"Cowie","year":"2020","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.jacc.2022.08.772_bib9","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1161\/CIRCULATIONAHA.118.035901","article-title":"Cardiovascular and renal outcomes with canagliflozin according to baseline kidney function","volume":"138","author":"Neuen","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2022.08.772_bib10","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1681\/ASN.2019111168","article-title":"Renal, cardiovascular, and safety outcomes of canagliflozin by baseline kidney function: a secondary analysis of the CREDENCE randomized trial","volume":"31","author":"Jardine","year":"2020","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.jacc.2022.08.772_bib11","doi-asserted-by":"crossref","first-page":"384","DOI":"10.2215\/CJN.15260920","article-title":"Kidney, cardiovascular, and safety outcomes of canagliflozin according to baseline albuminuria: a CREDENCE secondary analysis","volume":"16","author":"Jardine","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.jacc.2022.08.772_bib12","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.ahj.2013.05.007","article-title":"Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)\u2014a randomized placebo-controlled trial","volume":"166","author":"Neal","year":"2013","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacc.2022.08.772_bib13","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/dom.12829","article-title":"Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study-Renal (CANVAS-R): a randomized, placebo-controlled trial","volume":"19","author":"Neal","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jacc.2022.08.772_bib14","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1111\/dom.12924","article-title":"Optimizing the analysis strategy for the CANVAS Program\u2014a pre-specified plan for the integrated analyses of the CANVAS and CANVAS-R trials","volume":"19","author":"Neal","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jacc.2022.08.772_bib15","doi-asserted-by":"crossref","first-page":"581","DOI":"10.2215\/CJN.03190906","article-title":"Microalbuminuria and cardiovascular disease","volume":"2","author":"Weir","year":"2007","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.jacc.2022.08.772_bib16","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1093\/eurheartj\/ehv728","article-title":"Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME\u00ae trial","volume":"37","author":"Fitchett","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2022.08.772_bib17","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2022.08.772_bib18","unstructured":"Pratley RE, Jack SD, Cannon CP, McGuire DK, Cherney DZI. The VERTIS CV trial: cardiovascular outcomes following ertugliflozin treatment in patients with type 2 diabetes mellitus and atherosclerotic cardiovascular. Paper presented at: American Diabetes Association (ADA) Virtual 88th Scientific Sessions;\u00a02020."},{"key":"10.1016\/j.jacc.2022.08.772_bib19","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1161\/STROKEAHA.120.031623","article-title":"Effect of SGLT2 inhibitors on stroke and atrial fibrillation in diabetic kidney disease: results from the CREDENCE trial and meta-analysis","volume":"52","author":"Zhou","year":"2021","journal-title":"Stroke"},{"key":"10.1016\/j.jacc.2022.08.772_bib20","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1161\/CIRCULATIONAHA.120.050255","article-title":"Efficacy of ertugliflozin on heart failure-related events in patients with type 2 diabetes mellitus and established atherosclerotic cardiovascular disease: results of the VERTIS CV trial","volume":"142","author":"Cosentino","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2022.08.772_bib21","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1161\/CIRCULATIONAHA.120.051901","article-title":"Gradient of risk and associations with cardiovascular efficacy of ertugliflozin by measures of kidney function","volume":"143","author":"Cherney","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2022.08.772_bib22","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.2337\/dc21-0076","article-title":"The effect of dapagliflozin on albuminuria in DECLARE-TIMI 58","volume":"44","author":"Mosenzon","year":"2021","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jacc.2022.08.772_bib23","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.2215\/CJN.10140620","article-title":"Effects of canagliflozin in patients with baseline eGFR\u00a0<30\u00a0ml\/min per 1.73 m(2): subgroup analysis of the randomized CREDENCE trial","volume":"15","author":"Bakris","year":"2020","journal-title":"Clin J Am Soc Nephrol"}],"container-title":["Journal of the American College of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109722066943?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109722066943?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T13:50:56Z","timestamp":1760017856000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109722066943"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":23,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["S0735109722066943"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2022.08.772","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cardiovascular Effects of Canagliflozin in\u00a0Relation to Renal Function and\u00a0Albuminuria","name":"articletitle","label":"Article Title"},{"value":"Journal of the American College of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2022.08.772","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier on behalf of the American College of Cardiology Foundation","name":"copyright","label":"Copyright"}]}}